JMP Securities Increases Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $68.00

Mirum Pharmaceuticals (NASDAQ:MIRMGet Free Report) had its price objective upped by equities research analysts at JMP Securities from $66.00 to $68.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price target would suggest a potential upside of 132.48% from the stock’s current price.

MIRM has been the topic of several other reports. Citigroup increased their price target on shares of Mirum Pharmaceuticals from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $40.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, May 9th. Morgan Stanley increased their price target on shares of Mirum Pharmaceuticals from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Tuesday. HC Wainwright increased their price target on shares of Mirum Pharmaceuticals from $58.00 to $66.00 and gave the company a “buy” rating in a research note on Monday. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $48.00 price target on shares of Mirum Pharmaceuticals in a research note on Monday. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $53.64.

Check Out Our Latest Stock Analysis on MIRM

Mirum Pharmaceuticals Stock Down 11.4 %

Shares of NASDAQ:MIRM opened at $29.25 on Tuesday. The firm’s 50 day moving average price is $25.39 and its 200 day moving average price is $27.24. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -7.88 and a beta of 1.10. Mirum Pharmaceuticals has a fifty-two week low of $23.14 and a fifty-two week high of $35.56. The company has a quick ratio of 3.47, a current ratio of 3.68 and a debt-to-equity ratio of 1.31.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.14). The firm had revenue of $69.22 million during the quarter, compared to analyst estimates of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. As a group, equities research analysts predict that Mirum Pharmaceuticals will post -1.39 earnings per share for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt bought 2,000 shares of the stock in a transaction dated Wednesday, March 27th. The shares were acquired at an average cost of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the transaction, the chief financial officer now owns 14,000 shares in the company, valued at approximately $347,200. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CFO Eric Bjerkholt acquired 2,000 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were purchased at an average cost of $24.80 per share, for a total transaction of $49,600.00. Following the transaction, the chief financial officer now directly owns 14,000 shares in the company, valued at approximately $347,200. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Saira Ramasastry sold 5,000 shares of Mirum Pharmaceuticals stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $25.68, for a total transaction of $128,400.00. The disclosure for this sale can be found here. Insiders own 22.87% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. AJOVista LLC purchased a new position in Mirum Pharmaceuticals in the 4th quarter valued at $40,000. Wetzel Investment Advisors Inc. acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at $41,000. StepStone Group LP acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at $135,000. China Universal Asset Management Co. Ltd. lifted its holdings in Mirum Pharmaceuticals by 447.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,394 shares of the company’s stock valued at $159,000 after acquiring an additional 4,408 shares during the period. Finally, Quest Partners LLC acquired a new stake in Mirum Pharmaceuticals in the fourth quarter valued at $194,000.

Mirum Pharmaceuticals Company Profile

(Get Free Report)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Recommended Stories

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.